Business
SNDL Clears EU-GMP Audit at Atholville Cannabis Facility
Add MyCannabis.com to your preferred sources on Google
SNDL Inc. (SNDL ) announced on August 4, 2026, that it had completed a European Union Good Manufacturing Practice audit at its Atholville, New Brunswick cultivation facility, and that it expects to receive certification within 90 days of the audit’s completion. The milestone would restore the site’s lapsed EU-GMP credential and reopen a regulated export channel for Canadian-grown medical cannabis into Europe and other international markets.
EU-GMP is the standard most European medical-cannabis import jurisdictions require of overseas suppliers. A completed audit signals that the facility’s quality systems, cultivation controls, and documentation passed inspection by an EU-recognized auditing body. Certification is the administrative step that follows; SNDL said it anticipates receipt of the certificate within the next 90 days.
“This achievement is another example of SNDL’s commitment to disciplined execution,” said Zach George, Chief Executive Officer of SNDL. “The successful completion of this audit strengthens Atholville’s position as a strategically important asset and supports our ability to pursue international medical cannabis opportunities.” George credited Tim Main and Rebecca Knight, along with the broader New Brunswick team, for the result.
Atholville is among SNDL’s largest cultivation assets. The facility comprises roughly 380,000 square feet, with more than 110,000 square feet of cultivation canopy and current production capacity of approximately 4,500 kilograms per quarter. With targeted investment, the company says, the site could support output exceeding 30 tonnes.
What the audit clears the way for
Under the European Commission’s GMP framework, medicinal products and their active substances can only move into EU markets if they were manufactured to GMP standards equivalent to those in the bloc. For Canadian cannabis producers, an EU-GMP certificate issued for a specific facility is the practical licence to supply medical cannabis into Germany and other regulated European markets.
The EU also maintains mutual recognition agreements on GMP with several third countries, including Canada, though the detailed product scope varies by agreement. For cannabis, the operative requirement remains facility-level EU-GMP certification, which is what SNDL is now positioned to obtain for Atholville.
The facility’s path back to certification
Atholville is not new to this standard. SNDL acquired the site in November 2022 as the core asset of the Zenabis business, purchased out of a court-supervised creditor process. At the time of that acquisition, SNDL disclosed that the facility had previously held EU-GMP certification and had exported cannabis shipments to Malta, Israel and Australia. The August 4, 2026 announcement marks the site’s return to that standard under SNDL’s ownership.
The credential also arrives as SNDL reshapes its broader footprint. On July 27, 2026, the company completed its acquisition of certain Parallel assets, a U.S. medical-cannabis operator with 56 retail locations and three cultivation and manufacturing facilities across Florida, Texas and Massachusetts. That transaction gave SNDL indirect majority economic exposure to U.S. medical cannabis operations, a business the company expects to consolidate directly in the coming months.
SNDL’s recent financial picture
The audit lands a week after SNDL reported its second-quarter 2026 results, for the period ended June 30, 2026. Total net revenue came in at $235.8 million, down 3.7% from the same period a year earlier. The company’s cannabis operations segment, the business Atholville feeds, posted net revenue of $32.2 million for the quarter, a 10.1% decline, and an operating loss of $9.2 million, wider than the $3.1 million loss a year earlier. SNDL ended the quarter with $183.2 million in cash and cash equivalents and repurchased $23.5 million in common shares during the period.
A certified Atholville gives that segment a higher-value outlet for its output. Cannabis Operations’ international sales grew from $3.8 million in Q2 2025 to $5.0 million in Q2 2026.
What happens next
SNDL expects to receive the EU-GMP certificate for Atholville within 90 days of the August 4, 2026 audit completion, putting the anticipated certification date in early November 2026. The company has not announced specific supply agreements tied to the facility’s certification, but the credential is the precondition for them.
